SecSonar.com

Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Kymera Therapeutics, Inc. (KYMR) is a Biotechnology company based in US with a market capitalization of $6.7B. Revenue declined 16.7% year-over-year and free cash flow was negative at -$234.3M. This page tracks KYMR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 208 employees · IPO Aug 21, 2020

Valuation

Valuation & price

$82.21 · as of May 17, 2026 · -29.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.24

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$108$74.00$39.87Jul 25Dec 25Jun 26Jul 7, 25$43.81Jul 9, 25$45.18Jul 11, 25$44.48Jul 15, 25$44.91Jul 17, 25$46.35Jul 21, 25$45.14Jul 23, 25$46.43Jul 25, 25$45.79Jul 29, 25$43.70Jul 31, 25$43.75Aug 4, 25$43.66Aug 6, 25$41.35Aug 8, 25$40.62Aug 12, 25$39.87Aug 14, 25$41.55Aug 18, 25$43.62Aug 20, 25$42.35Aug 22, 25$44.10Aug 26, 25$43.87Aug 28, 25$41.75Sep 3, 25$43.30Sep 5, 25$43.51Sep 9, 25$43.48Sep 11, 25$46.20Sep 15, 25$47.28Sep 17, 25$48.12Sep 19, 25$49.13Sep 23, 25$50.87Sep 25, 25$53.74Sep 29, 25$58.50Oct 1, 25$54.66Oct 3, 25$57.90Oct 7, 25$56.92Oct 9, 25$57.02Oct 13, 25$59.89Oct 15, 25$62.89Oct 17, 25$59.83Oct 21, 25$58.32Oct 23, 25$57.76Oct 27, 25$60.85Oct 30, 25$61.44Nov 3, 25$59.72Nov 5, 25$59.89Nov 7, 25$58.66Nov 11, 25$63.37Nov 13, 25$63.63Nov 17, 25$64.10Nov 19, 25$64.82Nov 21, 25$66.04Nov 25, 25$66.04Nov 28, 25$67.88Dec 2, 25$64.27Dec 4, 25$66.23Dec 8, 25$94.30Dec 10, 25$89.89Dec 12, 25$89.68Dec 16, 25$84.19Dec 18, 25$79.63Dec 22, 25$84.35Dec 24, 25$83.13Dec 29, 25$80.35Jan 2, 26$72.76Jan 6, 26$73.46Jan 8, 26$74.98Jan 12, 26$73.09Jan 14, 26$75.21Jan 16, 26$69.54Jan 21, 26$70.74Jan 23, 26$69.93Jan 27, 26$72.15Jan 29, 26$73.91Feb 2, 26$75.62Feb 4, 26$77.70Feb 6, 26$79.59Feb 10, 26$79.49Feb 12, 26$84.02Feb 17, 26$84.84Feb 19, 26$86.50Feb 23, 26$88.43Feb 25, 26$90.68Mar 2, 26$90.10Mar 4, 26$86.11Mar 6, 26$83.49Mar 10, 26$84.58Mar 12, 26$77.50Mar 16, 26$79.60Mar 18, 26$79.14Mar 20, 26$77.91Mar 24, 26$74.42Mar 26, 26$80.18Mar 30, 26$79.48Apr 1, 26$84.93Apr 6, 26$85.27Apr 8, 26$87.13Apr 10, 26$85.05Apr 14, 26$89.87Apr 16, 26$86.14Apr 20, 26$86.93Apr 22, 26$88.77Apr 24, 26$84.91Apr 28, 26$83.85May 1, 26$80.71May 5, 26$82.71May 7, 26$84.63May 11, 26$84.10May 13, 26$85.59May 15, 26$82.21May 19, 26$78.14May 21, 26$80.61May 26, 26$80.77May 28, 26$81.46Jun 1, 26$78.47Jun 3, 26$73.21Jun 5, 26$74.13Jun 9, 26$76.91Jun 11, 26$82.96Jun 15, 26$85.59Jun 17, 26$89.90Jun 22, 26$99.45Jun 26, 26$108.12
$37.6852-week range$116.46
Loading valuation history…

Fundamentals

Key fundamentals

$6.7B

Market cap

-16.7%

Revenue growth (YoY)

100.0%

Gross margin

-$234.3M

Free cash flow (USD)

-$766M

Net debt

Net cash position

12.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$2.9MFY 2020$34.0MFY 2021$72.8MFY 2022$46.8MFY 2023$78.6MFY 2024$47.1MFY 2025$39.2M
$0$39.2M

Free cash flow by year

2018 → 2025

FY 2018$-19.2MFY 2019$17.4MFY 2020$79.0MFY 2021$-130.5MFY 2022$-155.9MFY 2023$-137.3MFY 2024$-207.3MFY 2025$-234.3M
-$19.2M-$234.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

22

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $9.2M · 10b5-1 PlanMainolfi Nello · Director, Chief Executive Officer · $9.2MJul 2, 2026Filing
  • Insider sellInsider Sell $387K · 10b5-1 PlanGoodman Noah · Chief Business Officer · $387.3KJul 2, 2026Filing
  • Insider sellInsider Sell $8.9M · 10b5-1 PlanJacobs Bruce N. · Chief Financial Officer · $8.9MJul 2, 2026Filing
  • Insider sellInsider Sell $8.3M · 10b5-1 PlanBooth Bruce · Director · $8.3MJul 2, 2026Filing
  • Insider sellInsider Sell $56.5M · 10b5-1 PlanBooth Bruce · Director · $56.5MJun 30, 2026Filing
  • Insider sellInsider Sell $3.4M · 10b5-1 PlanBooth Bruce · Director · $3.4MJun 30, 2026Filing
  • Insider sellInsider Sell $173.7MBVF PARTNERS L P/IL · Director · $173.7MJun 26, 2026Filing
  • Insider sellInsider Sell $44.0M · 10b5-1 PlanBooth Bruce · Director · $44MJun 25, 2026Filing
  • Insider sellInsider Sell $34.8M · 10b5-1 PlanBooth Bruce · Director · $34.8MJun 25, 2026Filing
  • Insider sellInsider Sell $570K · 10b5-1 PlanGoodman Noah · Chief Business Officer · $570KJun 25, 2026Filing

Questions

Frequently asked questions

What is Kymera Therapeutics, Inc.'s market cap?

Kymera Therapeutics, Inc. (KYMR) has a market capitalization of $6.7B.

What is KYMR's P/E ratio?

A meaningful P/E ratio is not available for KYMR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is KYMR's price-to-book (P/B) ratio?

KYMR trades at 4.24 times book value per share.

Are insiders buying KYMR stock?

SEC Form 4 filings show no open-market insider buys at Kymera Therapeutics, Inc. in the last 90 days (22 sells).

Same arena

Related companies in Biotechnology

PTGX

Protagonist Therapeutics, Inc.

$6.4B

ALKS

Alkermes plc

$7.1B

RYTM

Rhythm Pharmaceuticals, Inc.

$6.2B

PRAX

Praxis Precision Medicines, Inc.

$7.2B

CNTA

Centessa Pharmaceuticals plc

$6.1B

PTCT

PTC Therapeutics, Inc.

$6.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.